Nasdaq

Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal ...

BRIDGEWATER, N.J., March 4, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Business Insider

LAMIRA®, an eFlow® Technology nebulizer, expected to launch in Japan as a medical device for exclusive administration of ARIKAYCE® (amikacin liposome inhalation suspension)

STARNBERG, Germany, March 24, 2021 /PRNewswire/ -- PARI Pharma GmbH, a company focused on advanced aerosol delivery systems based on eFlow Technology, announces the authorization of the LAMIRA ...
Seeking Alpha

Insmed to Present New Data from Across its Respiratory Portfolio at the American Thoracic Society 2024 International Conference

—Additional Data from ARISE Study Evaluating the Impact of ARIKAYCE on Microbiologic Outcomes in Patients with Newly Diagnosed or Recurrent MAC Lung Disease to be Presented as Late-Breaker— —Data to ...
CNN

New NTM Treatment Guidelines Recommend Insmed's ARIKAYCE® (amikacin liposome inhalation suspension) for Treatment of Patients with Refractory MAC Lung Disease

BRIDGEWATER, N.J., July 7, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Seeking Alpha

INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 ARISE STUDY OF ARIKAYCE® (AMIKACIN LIPOSOME INHALATION SUSPENSION) IN PATIENTS WITH NTM LUNG ...

—QOL-B Respiratory Domain Shown to Work Effectively as Patient-Reported Outcome Tool in Patients with MAC Lung Disease; to be Proposed to FDA as Primary Endpoint in ENCORE with No Modifications— ...
ksn.com

Insmed to Showcase New Data Across Three Pillars at the American Thoracic Society 2022 International Conference

ARIKAYCE is delivered by a novel inhalation device, the Lamira ® Nebulizer System, developed by PARI. Lamira ® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a ...
Nasdaq

ARIKAYCE® (amikacin liposome inhalation suspension) Approved by Japan's Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by ...

BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ -- Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...
Pharmabiz

USPTO grants additional US patent for Insmed's Arikayce

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced that the US Patent and Trademark Office (USPTO) has ...
Morningstar

Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update

ARIKAYCE is delivered by a novel inhalation device, the Lamira® Nebulizer System, developed by PARI. Lamira® is a quiet, portable nebulizer that enables efficient aerosolization of ARIKAYCE via a ...
Business Insider

Insmed Announces Publication Discussing the Clinical Management of Common Respiratory Events Associated with ARIKAYCE® (Amikacin Liposome Inhalation Suspension) in the Journal ...

ARIKAYCE ® (amikacin liposome inhalation suspension) is delivered by a novel inhalation device, the Lamira ® Nebulizer System, developed by PARI. Lamira ® is a quiet, portable nebulizer that enables ...
The Trentonian

ARIKAYCE(R) (amikacin liposome inhalation suspension) Approved by Japan’s Ministry of Health, Labour and Welfare for the Treatment of Patients with NTM Lung Disease Caused by ...

BRIDGEWATER, N.J., March 23, 2021 /PRNewswire/ — Insmed Incorporated (Nasdaq:INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, ...